Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.
Leukemia
; 38(4): 918-922, 2024 Apr.
Article
in En
| MEDLINE
| ID: mdl-38368440
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Azacitidine
/
Leukemia, Myeloid, Acute
Limits:
Humans
Language:
En
Journal:
Leukemia
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
Year:
2024
Type:
Article
Affiliation country:
France